Goldman Sachs analyst Chris Shibutani maintained a Buy rating on Merck & Company (MRK – Research Report) yesterday and set a price target of $135.00.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Chris Shibutani has given his Buy rating due to a combination of factors including Merck & Company’s strong performance in its fourth quarter of 2024. The company reported revenues that exceeded expectations, driven primarily by the impressive growth of Keytruda, which saw a significant year-over-year increase in sales. Despite some challenges, such as the temporary pause in Gardasil shipments to China, Merck’s overall financial health remains robust.
Additionally, while Gardasil faced setbacks, other aspects of Merck’s portfolio, such as Winrevair, are showing positive progress in clinical development and market penetration. This well-rounded performance, along with Merck’s strategic adjustments in response to market conditions, supports the Buy rating, as the company continues to demonstrate its capability to achieve growth across its product lineup.
In another report released on January 30, Leerink Partners also maintained a Buy rating on the stock with a $118.00 price target.